New York Yankees’ Robinson Cano Has $200 Million at Stake When Tony Bosch Testifies About Biogenesis Lab
New York Yankees superstar Robinson Cano had better hope that there is no connection between his name and the Biogenesis lab formerly run by Tony Bosch. With Tuesday night’s news that Bosch will now work with MLB and give them names of former clients, there’s some speculation that Cano’s name might surface.
T.J. Quinn first reported the possible connection to ESPN in April when the spokeswoman for Cano’s foundation, Sonia Cruz, was listed as a former client of the Miami-area Biogenesis lab. At the time Cano denied having anything to do with the lab or even knowing who Bosch was. However, Bosch might have a different story when he speaks to MLB this week.
It wouldn’t be inconceivable for Cano to be on the list. After all, two of his former teammates and good friends, Alex Rodriguez and Melky Cabrera, were named as former clients in other documents. But the Cruz connection is the most troubling. Why would the spokeswoman of a major league star be a client at a lab now known for producing performance-enhancing drugs? It is possible that it is just a coincidence and Cano is innocent of any wrongdoing. However, just the speculation around his involvement could prove costly.
The timing couldn’t be worse for Cano who is about to sign a mega deal with some team this offseason, likely the Yankees. Widely regarded as the best second baseman in baseball and one of the games’ best hitters, Cano’s could sign a deal in the range of eight years and $200 million. If he’s on this list, that number will drop dramatically.
This is monumental news for Yankees fans around the country. While Alex Rodriguez will get most of the attention surrounding this Biogensis lab, the biggest concern for Yankee fans should be whether or not their best players has any real connection to the lab.
Tigers' Will Be Fine With Holaday As No. 2 Catcher
Although it would still make sense for the Detroit Tigers to add a left-handed hitting backup catcher, they should do just fine with Bryan Holaday. Read More